Business Context and Reporting Period
Company: Milestone Scientific Inc. (MLSS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Milestone Scientific designs and commercializes computer-controlled injection technologies for dental (CompuDent, STA) and medical (CompuMed, CompuFlo) applications. The company operates as a smaller reporting company and is currently focused on expanding its medical segment while managing costs in its core dental business.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Product Sales (Net) | $2,162,033 | $2,232,420 |
| Gross Profit | $1,564,024 | $1,647,435 |
| Gross Margin | 72.3% | 73.8% |
| Operating Loss | $(828,083) | $(1,997,853) |
| Net Loss | $(839,853) | $(1,994,586) |
| Net Loss Per Share (Basic/Diluted) | $(0.01) | $(0.02) |
| Cash and Cash Equivalents (End of Period) | $1,194,424 | $2,246,387 |
| Working Capital | $2,495,125 | $3,346,572 |
| Net Cash Provided by Operating Activities | $86,842 | $(1,008,089) |
| Total Debt (Convertible Notes) | $800,000 | $800,000 |
Note: Working capital calculated as Total Current Assets ($7,352,645) minus Total Current Liabilities ($4,857,520).
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased by approximately 3% ($70,387) year-over-year. Dental revenue dropped 6% due to lower international distributor demand influenced by geopolitical instability. Revenue from China fell to $0 from $110,000 in the prior year.
- Medical Segment Growth: Medical revenue increased 110% to $107,600, reflecting early-stage adoption of the CompuFlo Epidural System.
- Expense Reduction: Operating expenses decreased significantly by $1.25 million (34%). Selling, General, and Administrative (SG&A) expenses fell 27% primarily due to a 69.5% reduction in professional fees and the elimination of Research and Development (R&D) expenses ($0 in Q1 2026 vs. $369,120 in Q1 2025).
- Improved Operating Loss: The operating loss narrowed by 58% to $828,083, driven largely by cost-cutting measures.
- Positive Operating Cash Flow: The company generated $86,842 in operating cash flow, a reversal from the $1.0 million burn in the prior year, aided by inventory reductions and working capital management.
Guidance, Outlook, Risks, and Unusual Items
Subsequent Event: Private Placement
On April 20, 2026, the company completed a private placement of 7,962,963 units at $0.27 per unit, raising gross proceeds of approximately $2.15 million ($1.80 million cash and $351,000 debt conversion). This transaction improves liquidity but introduces significant dilution.
Going Concern and Liquidity
The filing states that recurring losses and an accumulated deficit of $134.6 million raise substantial doubt about the company's ability to continue as a going concern. While the April 2026 financing improved the position, future viability depends on generating revenue and securing additional capital.
Key Risks
- Delisting Risk: The company is not in compliance with NYSE American listing standards regarding minimum stockholders' equity ($2.3 million vs. required $4.0–$6.0 million). A compliance plan is in place with a deadline of April 8, 2027.
- China Exposure: Dual exposure to China as a manufacturing source and sales market creates risk from trade tensions, tariffs, and supply chain disruptions. China revenue was zero in Q1 2026.
- Medical Inventory: The company maintains a $1.0 million allowance against slow-moving medical finished goods due to slow adoption of the epidural system.
- Manufacturing Concentration: Reliance on informal arrangements with third-party manufacturers; termination could materially disrupt operations.
Investor Verification Checklist
- Capital Adequacy: Verify if the $1.8 million cash proceeds from the April 2026 private placement are sufficient to cover operating losses until the next financing or revenue inflection point.
- Listing Compliance: Monitor progress toward the $4 million stockholders' equity requirement to avoid delisting from NYSE American by April 2027.
- China Market Recovery: Confirm the status of the purchase order received in April 2026 for the Chinese market and assess the impact of tariffs on cost of goods sold.
- Medical Adoption: Evaluate the trajectory of CompuFlo sales to determine if the $1.0 million inventory allowance will need to be increased or if revenue can offset the write-down.
- Dilution Impact: Assess the impact of the new warrants (exercisable at $0.3375) and remaining convertible notes ($449,000 principal) on future share count and earnings per share.